Phaseline

Companies › LimmaTech Biologics

LimmaTech Biologics: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Infectious disease; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Shigella4V2
Tetravalent bioconjugate vaccine
–Phase 2Shigellosis–
LTB-NG6
Multivalent Neisseria gonorrhoeae vaccine
–Phase 1Neisseria GonorrheaApr 2027
Candi5V
Pentavalent bioconjugate vaccine against Candida species
–Phase 1Recurrent Vulvovaginal CandidiasisApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06615375Shigella4V2Phase 2ShigellosisInfectious diseaseApr 2026
NCT07758972LTB-NG6Phase 1Neisseria GonorrheaInfectious diseaseApr 2027
NCT06190509Candi5VPhase 1Recurrent Vulvovaginal CandidiasisInfectious diseaseApr 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Inventprise SK Bioscience Immorna Biotherapeutics Sinovac Life Sciences Bharat Biotech International

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.